Holen Sie sich die Stockscreener-App
114.17
2.77%
3.4048
Schlusskurs vom Vortag:
$110.77
Offen:
$110.79
24-Stunden-Volumen:
227.07K
Relative Volume:
0.31
Marktkapitalisierung:
$5.28B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-162.72M
KGV:
-31.10
EPS:
-3.6714
Netto-Cashflow:
$-144.89M
1W Leistung:
-1.01%
1M Leistung:
+8.93%
6M Leistung:
+107.32%
1J Leistung:
+1,035%
1-Tages-Spanne:
$110.79
$116.11
1-Wochen-Bereich:
$108.91
$119.69
52-Wochen-Spanne:
$7.575
$120.31
Celcuity Inc Stock (CELC) Company Profile
Firmenname
Celcuity Inc
Sektor
Branche
Telefon
763-392-0767
Adresse
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
114.05 | 5.13B | 0 | -162.72M | -144.89M | -3.6714 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.55 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.16 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.20 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.49 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.39 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | Eingeleitet | Guggenheim | Buy |
| 2025-07-01 | Fortgesetzt | Stifel | Buy |
| 2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-22 | Eingeleitet | Stifel | Buy |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-07 | Eingeleitet | Jefferies | Buy |
| 2021-07-29 | Eingeleitet | Cowen | Outperform |
| 2021-07-27 | Eingeleitet | Needham | Buy |
| 2021-01-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-11 | Fortgesetzt | Craig Hallum | Buy |
| 2018-11-20 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Celcuity Inc Aktie (CELC) Neueste Nachrichten
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - Yahoo Finance
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - The Motley Fool
Wolfe Research Maintains Outperform on Celcuity Inc (CELC) Mar 12, 2026 - Meyka
Celcuity’s Gedatolisib Advances With Pivotal Data And FDA Priority Review - simplywall.st
Celcuity publishes Phase 3 trial results in medical journal By Investing.com - Investing.com Nigeria
Celcuity stock maintained at Outperform by Wolfe on efficacy outlook - Investing.com
Celcuity Stock Pre-Market (-0.2%): Needham Raises Target on Strong Data Publication - Trefis
Buyback Watch: Can Celcuity Inc ride the EV waveEarnings Risk Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
Is Celcuity (CELC) Pricing Reflecting Its Sharp Rally And DCF-Heavy Discount? - simplywall.st
Assessing Celcuity (CELC) Valuation After Strong Recent Returns And Optimistic Growth Forecasts - Sahm
CELC: Gedatolisib delivers record efficacy in breast cancer, with launch and global expansion plans advancing - TradingView
Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing - Yahoo Finance
Celcuity (CELC) surges 662% in 2025 on breast cancer treatment trial results - MSN
Needham Raises Price Target for Celcuity (CELC) to $122 | CELC S - GuruFocus
Celcuity (NASDAQ:CELC) Price Target Raised to $122.00 - MarketBeat
Needham raises Celcuity stock price target on priority review status - Investing.com
Celcuity publishes Phase 3 trial results in medical journal - Investing.com South Africa
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology - Bitget
Celcuity Announces Publication of Results from PIK3CA - GlobeNewswire
Celcuity CEO Details Gedatolisib NDA, July PDUFA and Launch Plans at TD Cowen Conference - MarketBeat
Buybacks Report: Should I set a stop loss on Celcuity IncDollar Strength & Breakout Confirmation Alerts - baoquankhu1.vn
Understanding Momentum Shifts in (CELC) - Stock Traders Daily
Vanguard Group Inc. Raises Stock Position in Celcuity, Inc. $CELC - MarketBeat
CELC Stock Price, Quote & Chart | CELCUITY INC (NASDAQ:CELC) - ChartMill
CELC: Gedatolisib nears launch with strong trial data, regulatory momentum, and $10B+ peak potential - TradingView
TD Asset Management Inc Invests $3.60 Million in Celcuity, Inc. $CELC - MarketBeat
Artisan Partners Limited Partnership Boosts Stock Holdings in Celcuity, Inc. $CELC - MarketBeat
Celcuity Inc. (CELC) - DirectorsTalk Interviews
Celcuity To Participate in Upcoming Investor Conferences - The Manila Times
A Look At Celcuity (CELC) Valuation After Charles Romp Joins The Board And Gedatolisib Progress - simplywall.st
Celcuity Adds Oncology Veteran To Board As Gedatolisib Commercial Stakes Rise - Yahoo Finance
Bull Run: Should I set a stop loss on Celcuity IncJuly 2025 Opening Moves & Verified Swing Trading Watchlists - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (CELC) Movement - Stock Traders Daily
Is Celcuity’s (CELC) New Board Appointment a Turning Point for Its Commercial Strategy? - simplywall.st
Patient Square Capital LP Acquires Shares of 100,000 Celcuity, Inc. $CELC - MarketBeat
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position - AOL.com
Soleus Adds a Significant Number of Celcuity Shares - AOL.com
Perceptive Advisors Increases Stake in Celcuity - Intellectia AI
Avoro Capital Advisors LLC Acquires Significant Stake in Celcuit - GuruFocus
Avoro Capital Advisors LLC Acquires Significant Stake in Celcuity Inc - GuruFocus
Celcuity Inc. (CELC) Stock Analysis: Biotechnology Innovator’s 9.29% Upside Captures Investor Attention - DirectorsTalk Interviews
Celcuity, Inc. (NASDAQ:CELC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Decliners Report: How does Celcuity Inc correlate with Nasdaq2025 Buyback Activity & Fast Momentum Entry Tips - baoquankhu1.vn
Is It Too Late To Consider Celcuity (CELC) After Its 7x One Year Surge - simplywall.st
What Celcuity (CELC)'s Board Addition of Veteran Oncology Executive Means For Shareholders - Yahoo Finance
Commit To Purchase Celcuity At $45, Earn 17.8% Using Options - Nasdaq
Has Celcuity (CELC) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Soleus Capital Increases Stake in Celcuity - Intellectia AI
Is Celcuity’s New Oncology Commercial Leader Appointment Reshaping the Investment Case for CELC? - simplywall.st
Finanzdaten der Celcuity Inc-Aktie (CELC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):